Close Menu
  • FDA
  • Conferences
    • AACR
    • ASBRS
    • ASCO
    • SABCS
    • ASH
    • ESMO
    • MOASC
    • Upcoming Oncology Conferences
  • Cancers
    • Breast Cancer
    • Prostate Cancer Treatment
    • Lung Cancer Treatment
    • Gastrointestinal Cancer Treatment
    • Melanoma Skin Cancer Treatment
    • Non-Hodgkin Lymphoma
    • Kidney
    • Acute Lymphoblastic Leukemia
    • Acute Myelogenous Leukemia
    • Bone Metastases
    • Brain
    • Business Management
    • Cervical
    • Chronic Lymphocytic Leukemia
    • Chronic Myelogenous Leukemia
    • Colorectal
    • COVID-19
    • General
    • Genitourinary
    • Head and Neck
    • Help
    • Hematologic Malignancies
    • Hodgkin Lymphoma
    • Imaging
    • Immunotherapy
    • Liver
    • Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Disease
    • News
    • Non-Small Cell Lung Cancer
    • Other
    • Ovarian
    • Pancreatic
    • Patient Resources
    • Pediatric
    • Sarcoma
    • Sickle Cell
    • Small Cell Lung Cancer
    • Supportive Care
    • Testicular
    • Urology
    • Uterine
  • About
  • Contact
  • Advertise
    • Advertising and Services – Media Kit 2025 – OncologyTube.com
    • Oncology Press Release Distribution
Advertisement
X (Twitter) LinkedIn Facebook
X (Twitter) LinkedIn Facebook YouTube
OncologyTube
  • FDA
  • Conferences
    • AACR
    • ASBRS
    • ASCO
    • SABCS
    • ASH
    • ESMO
    • MOASC
    • Upcoming Oncology Conferences
  • Cancers
    • Breast Cancer
    • Prostate Cancer Treatment
    • Lung Cancer Treatment
    • Gastrointestinal Cancer Treatment
    • Melanoma Skin Cancer Treatment
    • Non-Hodgkin Lymphoma
    • Kidney
    • Acute Lymphoblastic Leukemia
    • Acute Myelogenous Leukemia
    • Bone Metastases
    • Brain
    • Business Management
    • Cervical
    • Chronic Lymphocytic Leukemia
    • Chronic Myelogenous Leukemia
    • Colorectal
    • COVID-19
    • General
    • Genitourinary
    • Head and Neck
    • Help
    • Hematologic Malignancies
    • Hodgkin Lymphoma
    • Imaging
    • Immunotherapy
    • Liver
    • Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Disease
    • News
    • Non-Small Cell Lung Cancer
    • Other
    • Ovarian
    • Pancreatic
    • Patient Resources
    • Pediatric
    • Sarcoma
    • Sickle Cell
    • Small Cell Lung Cancer
    • Supportive Care
    • Testicular
    • Urology
    • Uterine
  • About
  • Contact
  • Advertise
    • Advertising and Services – Media Kit 2025 – OncologyTube.com
    • Oncology Press Release Distribution
Subscribe
OncologyTube
[the_ad id="32629"]
Home » Page 4

Ontada: MDS [2023] Real-World Treatment and Survival USOncology – Ira Zackon MD

Myeloproliferative Disease 10 Mins Read

Treatment Patterns and Overall Survival (OS) Among Patients with Myelodysplastic Syndromes (MDS) Treated in the US Community Oncology Setting: A…

Idecabtagene Vicleucel Shows Effectiveness and Safety in High-Risk Multiple Myeloma Patients Krina Patel MD

Multiple Myeloma 11 Mins Read

Idecabtagene Vicleucel Shows Effectiveness and Safety in High-Risk Multiple Myeloma Patients Krina Patel MD By Krina Patel, MD, MSc So…

Odronextamab: Promising Results in Treating Relapsed/Refractory Follicular Lymphoma: Findings from Phase II Study ELM-2 Tae Min Kim MD

Lymphoma 7 Mins Read

Odronextamab: Promising Results in Treating Relapsed/Refractory Follicular Lymphoma: Findings from Phase II Study ELM-2 Tae Min Kim MD By Tae…

REGN5458: A Trial for Relapsed/Refractory Multiple Myeloma a BCMAxCD3 Bispecific Antibody Naresh Bumma MD

Multiple Myeloma 13 Mins Read

REGN5458: A Trial for Relapsed/Refractory Multiple Myeloma a BCMAxCD3 Bispecific Antibody Naresh Bumma MD By Naresh Bumma, MD – Ohio…

Zanubrutinib Outperforms Ibrutinib in Treating Relapsed/Refractory CLL / SLL Mehrdad Mobasher MD

Chronic Lymphocytic Leukemia 8 Mins Read

Zanubrutinib Outperforms Ibrutinib in Treating Relapsed/Refractory CLL/SLL Mehrdad Mobasher MD By Mehrdad Mobasher, MD, MPH The ALPINE study was a…

Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit: RenovoGem (Intra-Arterial Gemcitabine) Versus IV Gemcitabine and nab-paclitaxel for Pancreatic Cancer…

Pancreatic 2 Mins Read

Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit: RenovoGem (Intra-Arterial Gemcitabine) Versus IV Gemcitabine and nab-paclitaxel…

Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit: RenovoGem (Intra-Arterial Gemcitabine) Versus IV Gemcitabine and nab-paclitaxel for Pancreatic Cancer…

Pancreatic 4 Mins Read

Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit: RenovoGem (Intra-Arterial Gemcitabine) Versus IV Gemcitabine and nab-paclitaxel…

Renal Cell Carcinoma Trials: Guidelines and Eligibility According to ASCO-FCR: An Overview of RCC Trials Anna Odell

Kidney 8 Mins Read

Renal Cell Carcinoma Trials: Guidelines and Eligibility According to ASCO-FCR: An Overview of RCC Trials Anna Odell by Anna Odell,…

Renal Cell Carcinoma Trials: ASCO-FCR Guidelines for Renal Cell Carcinoma Trial Eligibility Ishann Sehgal

Kidney 5 Mins Read

Renal Cell Carcinoma Trials: ASCO-FCR Guidelines for Renal Cell Carcinoma Trial Eligibility Ishann Sehgal by Ishann Sehgal, City of Hope…

HER2 Low Breast Cancer: What Are the Latest Advancements in Novel Drug Antibody Conjugates for 2023? Yuan Yuan MD

Breast Cancer 6 Mins Read

HER2 Low Breast Cancer: What Are the Latest Advancements in Novel Drug Antibody Conjugates for 2023? Yuan Yuan MD By…

Belzutifan, Androgen Receptor Degraders, and Antibody Drug Conjugates

Genitourinary 4 Mins Read

Novel Therapies for Patients with Genetourinary Malignancies By: Rana R. McKay, MD – Medical Oncologist University of California San…

Lung Cancer EGFR: What Are The Latest Advanced Treatments in 2023? Insights from Ravi Salgia MD

Lung Cancer Treatment 8 Mins Read

Lung Cancer EGFR: What Are The Latest Advanced Treatments in 2023? Insights from Ravi Salgia MD By Ravi Salgia, MD,…

Urothelial Cancer: What’s New in 2023? [Slides] Targeted and Novel Therapies Nataliya Mar MD

Bladder 16 Mins Read

Urothelial Cancer: What’s New in 2023? Targeted and Novel Therapies Nataliya Mar MD By Nataliya Mar, MD Good afternoon, everyone.…

What is Sacituzumab Govitecan? [Slides] 2023 Latest breast cancer treatments

Breast Cancer 21 Mins Read

Insights on Breast Cancer Treatment: Yuan Yuan, MD’s Discussion on Sacituzumab Govitecan and Other Novel Treatments By Yuan Yuan, MD,…

How effective is mosunetuzumab in treating lymphoma? – [Slides] Elizabeth Budde, MD 2023 reviews new therapies

Lymphoma 27 Mins Read

How effective is mosunetuzumab in treating lymphoma? – Elizabeth Budde, MD 2023 reviews new therapies By Elizabeth Budde, Md, PhD…

Latest Clinical Trials in Thoracic Oncology [2023] [Slides] Ravi Salgia, MD

Lung Cancer Treatment 25 Mins Read

Lung Cancer Trials: Insights into Latest Clinical Trials in Thoracic Oncology – Expert Analysis from Ravi Salgia, MD By Ravi…

Abemaciclib: 2023 Kidney Cancer Breakthroughs Rana McKay, MD Slides

Kidney 20 Mins Read

Belzutifan and other Novel Therapies in Genitourinary Oncology 2023 By Rana McKay, MD – University of California San Diego We’re…

Gastrointestinal Malignancies Research Advancements: [Slides] Insights from Farshid Dayyani, MD

Gastrointestinal Cancer Treatment 21 Mins Read

Gastrointestinal Malignancies Research Advancements: Insights from Farshid Dayyani, MD By Farshid Dayyani, MD, PhD Thank you so much for inviting…

Health Inequity in Cancer Research: [Slides] Examining and Uncovering the Disparities by Hala Borno MD

Other 20 Mins Read

Health Inequity in Cancer Research: Examining and Uncovering the Disparities by Hala Borno MD By Hala Borno, MD What also…

Leptomeningeal Disease: Phase 1 Trial of BBB-Penetrant HER2 Inhibitor in Metastatic Breast Cancer Nicholas McAndrew MD

Breast Cancer 10 Mins Read

Leptomeningeal Disease: Phase 1 Trial of BBB-Penetrant HER2 Inhibitor in Metastatic Breast Cancer Nicholas McAndrew MD By Nicholas McAndrew, MD,…

Polygenic Risk Score: Validation of a Breast Cancer Risk Prediction Model in a Large Prospective Cohort Thomas Slavin, MD

Breast Cancer 12 Mins Read

Polygenic Risk Score: Validation of a Breast Cancer Risk Prediction Model in a Large Prospective Cohort Thomas Slavin, MD By…

Endocrine Therapy: 70-Gene MammaPrint Test Predicts Benefit in Early-Stage Breast Cancer Laura Van ’t Veer PhD

Breast Cancer 10 Mins Read

Endocrine Therapy: 70-Gene MammaPrint Test Predicts Benefit in Early-Stage Breast Cancer Laura Van ’t Veer By Laura Van ‘t Veer,…

NanoString: Intrinsic Subtypes and 21-Gene Assay Predict Recurrence in Early Stage HER2+ Breast Cancer from Saranya Chumsri MD

Breast Cancer 7 Mins Read

NanoString: Intrinsic Subtypes and 21-Gene Assay Predict Recurrence in Early Stage HER2+ Breast Cancer from Saranya Chumsri MD By Saranya…

Breast Cancer Index: Prospective Evaluation Insights from Kai Treuner PhD

Breast Cancer 10 Mins Read

Breast Cancer Index: Prospective Evaluation Insights from Kai Treuner PhD By Kai Treuner, PhD So the breast cancer index is…

PACE Trial: Palbociclib, Fulvestrant, and Avelumab in Endocrine Pre-treated Metastatic Breast Cancer Erica Mayer MD

Breast Cancer 7 Mins Read

PACE Trial: Palbociclib, Fulvestrant, and Avelumab in Endocrine Pre-treated Metastatic Breast Cancer Erica Mayer MD By Erica Mayer, MD So…

Polygenic Risk Score: Validation of a Breast Cancer Risk Prediction Model in a Large Prospective Cohort Thomas Slavin, MD

Breast Cancer 12 Mins Read

Polygenic Risk Score: Validation of a Breast Cancer Risk Prediction Model in a Large Prospective Cohort Thomas Slavin, MD By…

Endocrine Therapy: 70-Gene MammaPrint Test Predicts Benefit in Early-Stage Breast Cancer Laura Van ’t Veer PhD

Breast Cancer 10 Mins Read

Endocrine Therapy: 70-Gene MammaPrint Test Predicts Benefit in Early-Stage Breast Cancer Laura Van ’t Veer By Laura Van ‘t Veer,…

NanoString: Intrinsic Subtypes and 21-Gene Assay Predict Recurrence in Early Stage HER2+ Breast Cancer from Saranya Chumsri MD

Breast Cancer 7 Mins Read

NanoString: Intrinsic Subtypes and 21-Gene Assay Predict Recurrence in Early Stage HER2+ Breast Cancer from Saranya Chumsri MD By Saranya…

Breast Cancer Index: Prospective Evaluation Insights from Kai Treuner PhD

Breast Cancer 9 Mins Read

Breast Cancer Index: Prospective Evaluation Insights from Kai Treuner PhD By Kai Treuner, PhD So the breast cancer index is…

PACE Trial: Palbociclib, Fulvestrant, and Avelumab in Endocrine Pre-treated Metastatic Breast Cancer Erica Mayer MD

Breast Cancer 7 Mins Read

PACE Trial: Palbociclib, Fulvestrant, and Avelumab in Endocrine Pre-treated Metastatic Breast Cancer Erica Mayer MD By Erica Mayer, MD So…

Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit

Pancreatic 5 Mins Read

Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit: RenovoGem (Intra-Arterial Gemcitabine) Versus IV Gemcitabine and nab-paclitaxel…

Antibody-Drug Conjugate Advancements for Breast Cancer Treatment: Updates from SABCS 2022 by Leif Ellison MD

Breast Cancer 7 Mins Read

Antibody-Drug Conjugate Advancements for Breast Cancer Treatment: Updates from SABCS 2022 by Leif Ellisen MD By Leif Ellisen, MD So…

Invasive Lobular Breast Cancer: Steffi Oesterreich Shares Insightful Learning Sessions Exploring ILBC at SABCS 2022

Breast Cancer 7 Mins Read

Invasive Lobular Breast Cancer: Steffi Oesterreich Shares Insightful Learning Sessions Exploring ILBC at SABCS 2022 By Steffi Oesterreich, PhD So,…

Binimetinib: Combination Insights on the Treatment Strategy of Breast Cancer from SABCS 2022 Saranya Chumsri MD

Breast Cancer 8 Mins Read

Binimetinib: Combination Insights on the Treatment Strategy of Breast Cancer from SABCS 2022 Saranya Chumsri MD By Saranya Chumsri, MD…

Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit

Pancreatic 5 Mins Read

Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit: RenovoGem (Intra-Arterial Gemcitabine) Versus IV Gemcitabine and nab-paclitaxel…

Antibody-Drug Conjugate Advancements for Breast Cancer Treatment: Updates from SABCS 2022 by Leif Ellisen MD

Breast Cancer 7 Mins Read

iFrame is not supported! Antibody-Drug Conjugate Advancements for Breast Cancer Treatment: Updates from SABCS 2022 by Leif Ellisen MD By…

Invasive Lobular Breast Cancer: Steffi Oesterreich Shares Insightful Learning Sessions Exploring ILBC at SABCS 2022

Breast Cancer 7 Mins Read

iFrame is not supported! Invasive Lobular Breast Cancer: Steffi Oesterreich Shares Insightful Learning Sessions Exploring ILBC at SABCS 2022 By…

Binimetinib: Combination Insights on the Treatment Strategy of Breast Cancer from SABCS 2022 Saranya Chumsri MD

Breast Cancer 8 Mins Read

iFrame is not supported! Binimetinib: Combination Insights on the Treatment Strategy of Breast Cancer from SABCS 2022 Saranya Chumsri MD…

Geneoscopy: Efficacy of Non-Invasive Colorectal Cancer Screening Test Evaluated in the CRC-PREVENT Phase 3 Trial David Lieberman MD

Colorectal 10 Mins Read

Geneoscopy: Evaluating the Efficacy of a Non-Invasive Colorectal Cancer Screening Test: Findings from the CRC-PREVENT Phase 3 Trial Dr. David…

Adipocyte Vaccine: Presents Promising Results for Patients with Breast Cancer at SABCS 2022 Nora Disis MD

Breast Cancer 11 Mins Read

Adipocyte Vaccine: Presents Promising Results for Patients with Breast Cancer at SABCS 2022 Nora Disis MD By Nora Disis, MD…

AI Risk Assessment: Sybil A Reliable Deep Learning Model for Predicting Future Lung Cancer Risk

Lung Cancer Treatment 10 Mins Read

AI Risk Assessment: Sybil A Reliable Deep Learning Model for Predicting Future Lung Cancer Risk Dr. Florian Fintelmann By Florian…

Antibody-Drug Conjugate Advancements for Breast Cancer Treatment: Updates from SABCS 2022 by Leif Ellisen MD

Breast Cancer 7 Mins Read

Antibody-Drug Conjugate Advancements for Breast Cancer Treatment: Updates from SABCS 2022 by Leif Ellisen MD By Leif Ellisen, MD So…

Invasive Lobular Breast Cancer: Steffi Oesterreich Shares Insightful Learning Sessions Exploring ILBC at SABCS 2022

Breast Cancer 7 Mins Read

Invasive Lobular Breast Cancer: Steffi Oesterreich Shares Insightful Learning Sessions Exploring ILBC at SABCS 2022 By Steffi Oesterreich, PhD So,…

Binimetinib: Combination Insights on the Treatment Strategy of Breast Cancer from SABCS 2022 Saranya Chumsri MD

Breast Cancer 8 Mins Read

Binimetinib: Combination Insights on the Treatment Strategy of Breast Cancer from SABCS 2022 Saranya Chumsri MD By Saranya Chumsri, MD…

The Significance of ctDNA in Predicting Recurrence and Delaying Progression in Breast Cancer Patients Mridula George MD

Breast Cancer 7 Mins Read

The Significance of ctDNA in Predicting Recurrence and Delaying Progression in Breast Cancer Patients Mridula George MD By Mridula George,…

Geneoscopy: Evaluating the Efficacy of a Non-Invasive Colorectal Cancer Screening Test: Findings from the CRC-PREVENT Phase 3 Trial Dr. David Lieberman

Colorectal 11 Mins Read

iFrame is not supported! Geneoscopy: Evaluating the Efficacy of a Non-Invasive Colorectal Cancer Screening Test: Findings from the CRC-PREVENT Phase…

Adipocyte Vaccine: Presents Promising Results for Patients with Breast Cancer at SABCS 2022 Nora Disis MD

Breast Cancer 11 Mins Read

iFrame is not supported! Adipocyte Vaccine: Presents Promising Results for Patients with Breast Cancer at SABCS 2022 Nora Disis MD…

AI Risk Assessment: Sybil A Reliable Deep Learning Model for Predicting Future Lung Cancer Risk

Lung Cancer Treatment 10 Mins Read

iFrame is not supported! AI Risk Assessment: Sybil A Reliable Deep Learning Model for Predicting Future Lung Cancer Risk Dr.…

The Importance of ctDNA in Breast Cancer Diagnosis and Treatment Planning Mridula George MD

Breast Cancer 8 Mins Read

The Importance of ctDNA in Breast Cancer Diagnosis and Treatment Planning Mridula George MD By Mridula George, MD Breast cancer…

The Significance of ctDNA in Predicting Recurrence and Delaying Progression in Breast Cancer Patients Mridula George MD

Breast Cancer 7 Mins Read

iFrame is not supported! The Significance of ctDNA in Predicting Recurrence and Delaying Progression in Breast Cancer Patients Mridula George…

Geneoscopy: Evaluating the Efficacy of a Non-Invasive Colorectal Cancer Screening Test: Findings from the CRC-PREVENT Phase 3 Trial Dr. David Lieberman

Colorectal 11 Mins Read

Geneoscopy: Evaluating the Efficacy of a Non-Invasive Colorectal Cancer Screening Test: Findings from the CRC-PREVENT Phase 3 Trial Dr. David…

Adipocyte Vaccine: Presents Promising Results for Patients with Breast Cancer at SABCS 2022 Nora Disis MD

Breast Cancer 11 Mins Read

Adipocyte Vaccine: Presents Promising Results for Patients with Breast Cancer at SABCS 2022 Nora Disis MD By Nora Disis, MD…

Gemtuzumab Ozogamicin Enhances Outcomes in Intermediate Risk AML Patients Receiving Standard Induction Therapy: ASH 2022 Study Results Eunice Wang MD

Acute Myelogenous Leukemia 8 Mins Read

Gemtuzumab Ozogamicin Enhances Outcomes in Intermediate Risk AML Patients Receiving Standard Induction Therapy: ASH 2022 Study Results Eunice Wang MD…

Lung Cancer Screening Program: Cedars-Sinai Implements a Streamlined Approach by Sara Ghandehari MD

Lung Cancer Treatment 8 Mins Read

Lung Cancer Screening Program: Cedars-Sinai Implements a Streamlined Approach by Sara Ghandehari MD Sara Ghandehari, MD Cedars-Sinai is a non-profit…

AI Risk Assessment: Sybil A Reliable Deep Learning Model for Predicting Future Lung Cancer Risk Dr. Florian Fintelmann

Lung Cancer Treatment 10 Mins Read

AI Risk Assessment: Sybil A Reliable Deep Learning Model for Predicting Future Lung Cancer Risk Dr. Florian Fintelmann By Florian…

The Importance of ctDNA in Breast Cancer Diagnosis and Treatment Planning Mridula George MD

Breast Cancer 8 Mins Read

iFrame is not supported! The Importance of ctDNA in Breast Cancer Diagnosis and Treatment Planning Mridula George MD By Mridula…

Gemtuzumab Ozogamicin Enhances Outcomes in Intermediate Risk AML Patients Receiving Standard Induction Therapy: ASH 2022 Study Results Eunice Wang MD

Acute Myelogenous Leukemia 9 Mins Read

iFrame is not supported! Gemtuzumab Ozogamicin Enhances Outcomes in Intermediate Risk AML Patients Receiving Standard Induction Therapy: ASH 2022 Study…

Lung Cancer Screening Program: Cedars-Sinai Implements a Streamlined Approach by Sara Ghandehari MD

Lung Cancer Treatment 8 Mins Read

iFrame is not supported! Lung Cancer Screening Program: Cedars-Sinai Implements a Streamlined Approach by Sara Ghandehari MD Sara Ghandehari, MD…

Gemtuzumab Ozogamicin Enhances Outcomes in Intermediate Risk AML Patients Receiving Standard Induction Therapy: ASH 2022 Study Results Eunice Wang MD

Acute Myelogenous Leukemia 9 Mins Read

Gemtuzumab Ozogamicin Enhances Outcomes in Intermediate Risk AML Patients Receiving Standard Induction Therapy: ASH 2022 Study Results Eunice Wang MD…

Lung Cancer Screening Program: Cedars-Sinai Implements a Streamlined Approach by Sara Ghandehari MD

Lung Cancer Treatment 8 Mins Read

Lung Cancer Screening Program: Cedars-Sinai Implements a Streamlined Approach by Sara Ghandehari MD Sara Ghandehari, MD Cedars-Sinai is a non-profit…

The Significance of ctDNA in Predicting Recurrence and Delaying Progression in Breast Cancer Patients Mridula George MD

Breast Cancer 7 Mins Read

The Significance of ctDNA in Predicting Recurrence and Delaying Progression in Breast Cancer Patients Mridula George MD By Mridula George,…

The Importance of ctDNA in Breast Cancer Diagnosis and Treatment Planning Mridula George MD

Breast Cancer 8 Mins Read

The Importance of ctDNA in Breast Cancer Diagnosis and Treatment Planning Mridula George MD By Mridula George, MD Breast cancer…

Michael Pishvaian, MD, PhD – RenovoGem – Edited

Pancreatic 10 Mins Read

Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit: RenovoGem (Intra-Arterial Gemcitabine) Versus IV Gemcitabine and Nab-paclitaxel…

Elacestrant: FDA Grants Approval for Breast Cancer Treatment: Insights from Virginia Kaklamani

Breast Cancer 8 Mins Read

Elacestrant: FDA Grants Approval for Breast Cancer Treatment: Insights from Virginia Kaklamani By Virginia Kaklamani So after a patient’s cancer…

Elacestrant: FDA Grants Approval for Breast Cancer Treatment: Insights from Virginia Kaklamani

Breast Cancer 8 Mins Read

iFrame is not supported! Elacestrant: FDA Grants Approval for Breast Cancer Treatment: Insights from Virginia Kaklamani By Virginia Kaklamani So…

FLEX Trial Breast Cancer: SABCS 2022 Mehran Habibi MD Looking at Gene Mutations

Breast Cancer 9 Mins Read

FLEX Trial Breast Cancer: SABCS 2022 Mehran Habnibi MD Looking at Gene Mutations By Mehran Habibi, MD, MBA The new…

FLEX Trial Breast Cancer: SABCS 2022 Mehran Habibi MD Looking at Gene Mutations

Breast Cancer 9 Mins Read

iFrame is not supported! FLEX Trial Breast Cancer: SABCS 2022 Mehran Habnibi MD Looking at Gene Mutations By Mehran Habibi,…

Elacestrant: FDA Grants Approval for Breast Cancer Treatment: Insights from Virginia Kaklamani

Breast Cancer 8 Mins Read

Elacestrant: FDA Grants Approval for Breast Cancer Treatment: Insights from Virginia Kaklamani By Virginia Kaklamani So after a patient’s cancer…

FLEX Trial Breast Cancer: SABCS 2022 Mehran Habibi MD Looking at Gene Mutations

Breast Cancer 9 Mins Read

FLEX Trial Breast Cancer: SABCS 2022 Mehran Habnibi MD Looking at Gene Mutations By Mehran Habibi, MD, MBA The new…

Sacituzumab Govitecan: SABCS 2022 Sara Tolaney vs Chemo TROPiCS-02

Breast Cancer 9 Mins Read

Sacituzumab Govitecan: SABCS 2022 Sara Tolaney vs Chemo TROPiCS-02 By Sara Tolaney, MD What were the patient-reported outcomes from the…

Sacituzumab Govitecan: SABCS 2022 Sara Tolaney vs Chemo TROPiCS-02

Breast Cancer 9 Mins Read

iFrame is not supported! Sacituzumab Govitecan: SABCS 2022 Sara Tolaney vs Chemo TROPiCS-02 By Sara Tolaney, MD What were the…

Trodelvy (Sacituzumab Govitecan): SABCS 2022 Sara Tolaney vs Chemo TROPiCS-02

Breast Cancer 9 Mins Read

Sacituzumab Govitecan: SABCS 2022 Sara Tolaney vs Chemo TROPiCS-02 By Sara Tolaney, MD What were the patient-reported outcomes from the…

Heterogeneity: SABCS 2022 Adrian Lee PhD Highlighted Research in Transcriptomics

Breast Cancer 10 Mins Read

Heterogeneity: SABCS 2022 Adrian Lee PhD Highlighted Research in Transcriptomics By Professor Adrian Lee How can heterogeneity in breast cancer…

Heterogeneity: SABCS 2022 Adrian Lee PhD Highlighted Research in Transcriptomics

Breast Cancer 10 Mins Read

iFrame is not supported! Heterogeneity: SABCS 2022 Adrian Lee PhD Highlighted Research in Transcriptomics By Professor Adrian Lee How can…

Heterogeneity: SABCS 2022 Adrian Lee PhD Highlighted Research in Transcriptomics

Breast Cancer 10 Mins Read

Heterogeneity: SABCS 2022 Adrian Lee PhD Highlighted Research in Transcriptomics By Professor Adrian Lee How can heterogeneity in breast cancer…

Brentuximab: ASH 2022 Dr. Mitul Gandhi Updated Efficacy and Safety Results

Hodgkin Lymphoma 9 Mins Read

Brentuximab: ASH 2022 Dr. Mitul Gandhi Updated Efficacy and Safety Results By Mitul Gandhi, MD What were the results of…

Brentuximab: ASH 2022 Dr. Mitul Gandhi Updated Efficacy and Safety Results

Hodgkin Lymphoma 9 Mins Read

iFrame is not supported! Brentuximab: ASH 2022 Dr. Mitul Gandhi Updated Efficacy and Safety Results By Mitul Gandhi, MD What…

Brentuximab: ASH 2022 Dr. Mitul Gandhi Updated Efficacy and Safety Results

Hodgkin Lymphoma 9 Mins Read

Brentuximab: ASH 2022 Dr. Mitul Gandhi Updated Efficacy and Safety Results By Mitul Gandhi, MD What were the results of…

Odronextamab: ASH 2022 Won Seog Kim MD Prespecified Analysis ELM-2 in DLBCL

Lymphoma 6 Mins Read

Odronextamab: ASH 2022 Won Seog Kim MD Prespecified Analysis ELM-2 in DLBCL By Won Seog Kim, MD How can Odronextamab…

Odronextamab: ASH 2022 Won Seog Kim MD Prespecified Analysis ELM-2 in DLBCL

Lymphoma 6 Mins Read

iFrame is not supported! Odronextamab: ASH 2022 Won Seog Kim MD Prespecified Analysis ELM-2 in DLBCL By Won Seog Kim,…

Odronextamab: ASH 2022 Won Seog Kim MD Prespecified Analysis ELM-2 in DLBCL

Lymphoma 6 Mins Read

Odronextamab: ASH 2022 Won Seog Kim MD Prespecified Analysis ELM-2 in DLBCL By Won Seog Kim, MD How can Odronextamab…

eNewseletter: Phase 3 Ithaca Isatuximab: ASH 2022 Irene Ghobrial MD

Hematologic Malignancies 2 Mins Read

Phase 3 ITHACA Study Results: Latest Insights on Isatuximab presented from ASH 2022 discussed by Dr. Irene Ghobrial from…

Pembrolizumab’s approval in this setting does not mean clinical value for Adjuvant Therapy for Resected NSCLC Jack West MD

Non-Small Cell Lung Cancer 12 Mins Read

Pembrolizumab’s approval in this setting does not mean clinical value for Adjuvant Therapy for Resected NSCLC By Jack West, MD…

Pembrolizumab’s approval in this setting does not mean clinical value for Adjuvant Therapy for Resected NSCLC Jack West MD

Non-Small Cell Lung Cancer 12 Mins Read

iFrame is not supported! Pembrolizumab’s approval in this setting does not mean clinical value for Adjuvant Therapy for Resected NSCLC…

Pembrolizumab’s approval in this setting does not mean clinical value for Adjuvant Therapy for Resected NSCLC Jack West MD

Non-Small Cell Lung Cancer 12 Mins Read

Pembrolizumab’s approval in this setting does not mean clinical value for Adjuvant Therapy for Resected NSCLC By Jack West, MD…

2023 ASH Multiple Myeloma Updates [Slides] – Lisa Lee, MD MOASC

Multiple Myeloma 16 Mins Read

2023 ASH BCMA & Multiple Myeloma Updates with Slides by: Lisa Lee, MD – Assistant Professor — Division of Hematology-Oncology, Department…

2023 ASH Hematopoietic Stem Cell Transplantation [Slides] – Stefan Ciurea, MD MOASC

Hematologic Malignancies 8 Mins Read

ASH Meeting 2022 – Hematopoietic Stem Cell Transplantation with Tacrolimus Updates By Stefan O. Ciurea, MD from UCI Health So…

2023 ASH Multiple Myeloma [Slides] – Lisa Lee, MD MOASC

Multiple Myeloma 3 Mins Read

What ASH abstracts stood out to you most in multiple myeloma? By Lisa X. Lee, MD from UCI Health At…

2023 ASH Acute Myeloid Leukemia [Slides] – Deepa Jeyakumar, MD MOASC

Acute Myelogenous Leukemia 3 Mins Read

Myelodysplastic Syndromes Treatment Update for 2023 By Deepa Jeyakumar, MD from UCI Health I think what’s very exciting is that…

2023 ASH CLL and Lymphoma [Slides] – Elizabeth Brém, MD MOASC

Chronic Lymphocytic Leukemia 4 Mins Read

Zanubrutinib compared to ibrutinib in chronic lymphocytic leukemia By Elizabeth Brém, MD from UCI Health We focused basically on two…

2023 ASH Benign Hematology [Slides] – Zahra Pakbaz, MD MOASC

Hematologic Malignancies 4 Mins Read

Women with recurrent miscarriage were treated with low molecular weight heparin versus usual pregnancy care By Zahra Pakbaz, MD from…

2023 ASH Hematopoietic Stem Cell & Tacrolimus Updates [Slides] – Stefan Ciurea MD – MOASC

Hematologic Malignancies 17 Mins Read

ASH Meeting 2022 – Hematopoietic Stem Cell Transplantation with Tacrolimus UpdatesBy: Stefan O. Ciurea, MD – Director, Hematopoietic Stem Cell…

Inotuzumab and MRD Understanding the Importance of Targeted Therapy in Cancer Treatment

Acute Myelogenous Leukemia 6 Mins Read

iFrame is not supported! Inotuzumab and MRD Understanding the Importance of Targeted Therapy in Cancer Treatment Summarized from Van Huynh,…

RenovoGem: PK Study Paula Novelli For Locally Advanced Pancreatic Cancer

Pancreatic 13 Mins Read

Intra-arterial Versus Intravenous Gemcitabine Administration: PK Substudy within the Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer By…

RenovoGem: PK Study Paula Novelli For Locally Advanced Pancreatic Cancer

Pancreatic 14 Mins Read

iFrame is not supported! Intra-arterial Versus Intravenous Gemcitabine Administration: PK Substudy within the Phase III TIGeR-PaC Clinical Trial in Locally…

RenovoGem: PK Study Paula Novelli For Locally Advanced Pancreatic Cancer

Pancreatic 13 Mins Read

Intra-arterial Versus Intravenous Gemcitabine Administration: PK Substudy within the Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer By…

2023 ASH AML Update [Slides] – Kiran Naqvi, MD MOASC

Acute Myelogenous Leukemia 5 Mins Read

Myelodysplastic Syndromes Treatment Update for 2023 ASH AML Inotuzumab Update [Slides] – Kiran Naqvi, MD MOASC By Kiran Naqvi, MD…

MRD: 2023 ASH ALL Inotuzumab Update [Slides] – Van Huynh, MD MOASC

Acute Lymphoblastic Leukemia 8 Mins Read

MRD: Inotuzumab, GMALL, Ponatinib & Blinatumomab ASH Updates in Acute Lymphoblastic Leukemia/Immunotherapy By Van Huynh, MD Today I spoke at…

2023 Myelodysplastic Syndrome Update [Slide] Jeyakumar MD – MOASC

Myeloproliferative Disease 17 Mins Read

Myelodysplastic Syndromes Treatment Update for 2023 So briefly with regard to myelodysplastic syndromes MDS, I just wanted to discuss some…

2023 ASH ALL Inotuzumab Update [Slides] – Van Huynh, MD MOASC

Acute Lymphoblastic Leukemia 19 Mins Read

Inotuzumab, GMALL, Ponatinib & Blinatumomab ASH Updates in Acute Lymphoblastic Leukemia By Van Huynh, MD Updates in acute lymphoblastic leukemia…

2023 ASH CLL Update [Slides] – Elizabeth Brem- MOASC zanubrutinib

Chronic Lymphocytic Leukemia 18 Mins Read

Zanubrutinib compared to ibrutinib in chronic lymphocytic leukemia So I’m gonna start with chronic lymphocytic leukemia. And as part of…

2023 ASH Etavopivat Update [Slides] – Zahra Pakbaz MD MOASC

Hematologic Malignancies 21 Mins Read

2023 ASH Pregnancy Update Slides Etavopivat treatment Low molecular weight heparin versus a standard pregnancy care for women with recurrent…

2023 ASH AML Updates [Slides] – Kiran Naqvi MD – MOASC

Acute Myelogenous Leukemia 26 Mins Read

2023 ASH AML Updates [Slides] – Kiran Naqvi MD – MOASC Acute myeloid leukemia updates from our recent ASH from…

Liso-cel: ASH 2022 Jeremy Abramson vs. SOC SCT and ASCT in RR LBCL

Lymphoma 12 Mins Read

Liso-cel: ASH 2022 Jeremy Abramson vs. SOC SCT and ASCT in RR LBCL By Jeremy Abramson, MD What did the…

Liso-cel: ASH 2022 Jeremy Abramson vs. SOC SCT and ASCT in RR LBCL

Lymphoma 12 Mins Read

iFrame is not supported! Liso-cel: ASH 2022 Jeremy Abramson vs. SOC SCT and ASCT in RR LBCL By Jeremy Abramson,…

Liso-cel: ASH 2022 Jeremy Abramson vs. SOC SCT and ASCT in RR LBCL

Lymphoma 12 Mins Read

Liso-cel: ASH 2022 Jeremy Abramson vs. SOC SCT and ASCT in RR LBCL By Jeremy Abramson, MD What did the…

MRD: ASH 2022 Ben Derman the MRD2STOP Guide

Multiple Myeloma 17 Mins Read

MRD: ASH 2022 Ben Derman the MRD2STOP Guide By Ben Derman, MD How can the MRD2STOP guide help patients with…

MRD: ASH 2022 Ben Derman the MRD2STOP Guide

Multiple Myeloma 17 Mins Read

iFrame is not supported! MRD: ASH 2022 Ben Derman the MRD2STOP Guide By Ben Derman, MD How can the MRD2STOP…

MRD: ASH 2022 Ben Derman the MRD2STOP Guide

Multiple Myeloma 17 Mins Read

MRD: ASH 2022 Ben Derman the MRD2STOP Guide By Ben Derman, MD How can the MRD2STOP guide help patients with…

Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study

Multiple Myeloma 16 Mins Read

Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study By Irene Ghobrial, MD What does the Ithaca clinical trials updated…

Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study

Acute Lymphoblastic Leukemia 16 Mins Read

iFrame is not supported! Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study By Irene Ghobrial, MD What does the…

Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study

Multiple Myeloma 16 Mins Read

Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study By Irene Ghobrial, MD What does the Ithaca clinical trials updated…

The Potential of Next Generation BTK Inhibitors in CLL / SLL

Chronic Lymphocytic Leukemia 1 Min Read

Emerging BTK inhibitors are positioned to change the landscape and impact your chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) treatment…

Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes

Multiple Myeloma 9 Mins Read

Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes By Joshua Richter, MD What is a Anti-CD38? And How…

Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes

Multiple Myeloma 9 Mins Read

iFrame is not supported! Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes By Joshua Richter, MD What is…

Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes

Multiple Myeloma 9 Mins Read

Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes By Joshua Richter, MD What is a Anti-CD38? And How…

Pembro: ASH 2022 Craig Sauter After auto-SCT in T-Cell NHL

Non-Hodgkin Lymphoma 9 Mins Read

Pembro: ASH 2022 Craig Sauter After auto-SCT in T-Cell NHL By Craig Sauter, MD How does Pembrolizumab (MK-3475), also known…

Pembro: ASH 2022 Craig Sauter After auto-SCT in T-Cell NHL

Non-Hodgkin Lymphoma 9 Mins Read

iFrame is not supported! Pembro: ASH 2022 Craig Sauter After auto-SCT in T-Cell NHL By Craig Sauter, MD How does…

Pembro: ASH 2022 Craig Sauter After auto-SCT in T-Cell NHL

Non-Hodgkin Lymphoma 9 Mins Read

Pembro: ASH 2022 Craig Sauter After auto-SCT in T-Cell NHL By Craig Sauter, MD How does Pembrolizumab (MK-3475), also known…

MPN: ASH 2022 Abdulraheem Yacoub Add-on of Parsaclisib

Hematologic Malignancies 15 Mins Read

MPN: ASH 2022 Abdulraheem Yacoub Add-on of Parsaclisib By Abdulraheem Yacoub, MD What were the results of the MPN (myeloproliferative…

MPN: ASH 2022 Abdulraheem Yacoub Add-on of Parsaclisib

Myeloproliferative Disease 15 Mins Read

iFrame is not supported! MPN: ASH 2022 Abdulraheem Yacoub Add-on of Parsaclisib By Abdulraheem Yacoub, MD What were the results…

MPN: ASH 2022 Abdulraheem Yacoub Add-on of Parsaclisib

Hematologic Malignancies 15 Mins Read

MPN: ASH 2022 Abdulraheem Yacoub Add-on of Parsaclisib By Abdulraheem Yacoub, MD What were the results of the MPN (myeloproliferative…

PTG-300: ASH 2022 Srdan Verstovsek Verify Phase 3 Clinical Trial

Hematologic Malignancies 9 Mins Read

PTG-300: ASH 2022 Srdan Verstovsek Verify Phase 3 Clinical Trial By Srdan Verstovsek, MD, PhD What were the results of…

PTG-300: ASH 2022 Srdan Verstovsek Verify Phase 3 Clinical Trial

Hematologic Malignancies 9 Mins Read

iFrame is not supported! PTG-300: ASH 2022 Srdan Verstovsek Verify Phase 3 Clinical Trial By Srdan Verstovsek, MD, PhD What…

PTG-300: ASH 2022 Srdan Verstovsek Verify Phase 3 Clinical Trial

Hematologic Malignancies 9 Mins Read

PTG-300: ASH 2022 Srdan Verstovsek Verify Phase 3 Clinical Trial By Srdan Verstovsek, MD, PhD What were the results of…

Side Effects of ROS1-TKIs – 2022 Program: Targeted Therapies Forum

Non-Small Cell Lung Cancer 1 Min Read

For this year’s Targeted Therapies Forum, Dr. Chul Kim, Assistant Professor, Georgetown University; Hematology/ Medical Oncology; Attending Physician at MedStar…

Side Effects of ALK-TKIs – 2022 Program: Targeted Therapies Forum

Non-Small Cell Lung Cancer 1 Min Read

For this year’s Targeted Therapies Forum, Dr. Chul Kim, Assistant Professor, Georgetown University; Hematology/ Medical Oncology; Attending Physician at MedStar…

Side Effects of EGFR-TKIs: Pneumonitis and Cardiotoxicity – 2022 Program: Targeted Therapies Forum

Non-Small Cell Lung Cancer 1 Min Read

For this year’s Targeted Therapies Forum, Dr. Chul Kim, Assistant Professor, Georgetown University; Hematology/ Medical Oncology; Attending Physician at MedStar…

Managing Side Effects of EGFR-TKIs: Stomatitis and Diarrhea – 2022 Program: Targeted Therapies Forum

Non-Small Cell Lung Cancer 1 Min Read

For this year’s Targeted Therapies Forum, Dr. Chul Kim, Assistant Professor, Georgetown University; Hematology/ Medical Oncology; Attending Physician at MedStar…

Dermatologic Side Effects of EGFR-TKIs – 2022 Program: Targeted Therapies Forum

Non-Small Cell Lung Cancer 1 Min Read

For this year’s Targeted Therapies Forum, Dr. Chul Kim, Assistant Professor, Georgetown University; Hematology/ Medical Oncology; Attending Physician at MedStar…

Oligoprogression in EGFR Mutant NSCLC – 2022 Program:Targeted Therapies Forum

Non-Small Cell Lung Cancer 1 Min Read

For this year’s Targeted Therapies Forum, Dr. Narjust Florez, Associate Director, Cancer Care Equity Program, Dana-Farber Cancer Institute; Assistant Professor…

Treatment of Oligoprogression – 2022 Program: Targeted Therapies Forum

General 1 Min Read

For this year’s Targeted Therapies Forum, Dr. Narjust Florez, Associate Director, Cancer Care Equity Program, Dana-Farber Cancer Institute; Assistant Professor…

Identifying Oligoprogression in a Patient – 2022 Program: Targeted Therapies Forum

General 1 Min Read

For this year’s Targeted Therapies Forum, Dr. Narjust Florez, Associate Director, Cancer Care Equity Program, Dana-Farber Cancer Institute; Assistant Professor…

What is Oligoprogression? – 2022 Program:Targeted Therapies Forum

General 1 Min Read

For this year’s Targeted Therapies Forum, Dr. Narjust Florez, Associate Director, Cancer Care Equity Program, Dana-Farber Cancer Institute; Assistant Professor…

Pembro: ASH 2022 Mwanasha Merrill Addition After Auto-SCT T-Cell NHL

Lymphoma 8 Mins Read

Pembro: ASH 2022 Mwanasha Merrill Addition After Auto-SCT T-Cell NHL By Mwanasha Merrill, MD How can Pembro (MK-3475) help patients…

Pembro: ASH 2022 Mwanasha Merrill Addition After Auto-SCT T-Cell NHL

Lymphoma 8 Mins Read

iFrame is not supported! Pembro: ASH 2022 Mwanasha Merrill Addition After Auto-SCT T-Cell NHL By Mwanasha Merrill, MD How can…

Pembro: ASH 2022 Mwanasha Merrill Addition After Auto-SCT T-Cell NHL

Lymphoma 8 Mins Read

Pembro: ASH 2022 Mwanasha Merrill Addition After Auto-SCT T-Cell NHL By Mwanasha Merrill, MD How can Pembro (MK-3475) help patients…

MRD: ASH 2022 Gayathri Ravi Induction Quadruplet Therapy in NDMM

Multiple Myeloma 10 Mins Read

MRD: ASH 2022 Gayathri Ravi Induction Quadruplet Therapy in NDMM By Gayathri Ravi, MD What can induction quadruplet therapy do…

ASH 2022 Gayathri Ravi Induction Quadruplet Therapy in NDMM

Multiple Myeloma 10 Mins Read

iFrame is not supported! MRD: ASH 2022 Gayathri Ravi Induction Quadruplet Therapy in NDMM By Gayathri Ravi, MD What can…

MRD: ASH 2022 Gayathri Ravi Induction Quadruplet Therapy in NDMM

Multiple Myeloma 10 Mins Read

MRD: ASH 2022 Gayathri Ravi Induction Quadruplet Therapy in NDMM By Gayathri Ravi, MD What can induction quadruplet therapy do…

PI3Kα: SABCS 2022 Axel Hoos STX-478 Xenograft Models Breast Cancer

Breast Cancer 11 Mins Read

PI3Kα: SABCS 2022 Axel Hoos STX-478 Xenograft Models Breast Cancer How can a PI3Kα inhibitor help patients suffering with breast…

PI3Kα: SABCS 2022 Axel Hoos STX-478 Xenograft Models Breast Cancer

Breast Cancer 11 Mins Read

iFrame is not supported! PI3Kα: SABCS 2022 Axel Hoos STX-478 Xenograft Models Breast Cancer How can a PI3Kα inhibitor help patients…

PI3Kα: SABCS 2022 Axel Hoos STX-478 Xenograft Models Breast Cancer

Breast Cancer 11 Mins Read

PI3Kα: SABCS 2022 Axel Hoos STX-478 Xenograft Models Breast Cancer How can a PI3Kα inhibitor help patients suffering with breast…

Sacituzumab Govitecan: SABCS 2022 Hope Rugo EAIRs of AEs TROPiCS-02

Breast Cancer 12 Mins Read

Sacituzumab Govitecan: SABCS 2022 Hope Rugo EAIRs of AEs TROPiCS-02 What does Sacituzumab Govitecan trial results show for patients with…

Sacituzumab Govitecan: SABCS 2022 Hope Rugo EAIRs of AEs TROPiCS-02

Breast Cancer 12 Mins Read

iFrame is not supported! Sacituzumab Govitecan: SABCS 2022 Hope Rugo EAIRs of AEs TROPiCS-02 What does Sacituzumab Govitecan trial results…

Sacituzumab Govitecan: SABCS 2022 Hope Rugo EAIRs of AEs TROPiCS-02

Breast Cancer 12 Mins Read

Sacituzumab Govitecan: SABCS 2022 Hope Rugo EAIRs of AEs TROPiCS-02 What does Sacituzumab Govitecan trial results show for patients with…

ARV-471: SABCS 2022 Ron Peck Phase 2 Expansion VERITAC Trial

Breast Cancer 7 Mins Read

ARV-471: SABCS 2022 Ron Peck Phase 2 Expansion VERITAC Trial What can this PROTAC estrogen receptor degrader do for patients…

ARV-471: SABCS 2022 Phase 2 Expansion VERITAC Trial

Breast Cancer 7 Mins Read

iFrame is not supported! ARV-471: SABCS 2022 Ron Peck Phase 2 Expansion VERITAC Trial What can this PROTAC estrogen receptor…

ARV-471: SABCS 2022 Ron Peck Phase 2 Expansion VERITAC Trial

Breast Cancer 7 Mins Read

ARV-471: SABCS 2022 Ron Peck Phase 2 Expansion VERITAC Trial What can this PROTAC estrogen receptor degrader do for patients…

The Importance of Breast Cancer Screening – 2022 Program: Testing and Early Diagnosis

Breast Cancer 1 Min Read

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University…

Treatment After Diagnosis of Breast Cancer – 2022 Program: Testing and Early Diagnosis

Breast Cancer 1 Min Read

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University…

Symptoms of Breast Cancer – 2022 Program: Testing and Early Diagnosis

Breast Cancer 1 Min Read

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University…

Anomalies on Breast Cancer Imaging: Next Steps – 2022 Program: Testing and Early Diagnosis

Breast Cancer 1 Min Read

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University…

Types of Imaging Tests for Breast Cancer – 2022 Program: Testing and Early Diagnosis

Breast Cancer 1 Min Read

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University…

Prevalence of Breast Cancer and Tools for Early Detection -2022 Program: Testing and Early Diagnosis

Breast Cancer 1 Min Read

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University…

The Importance of Prostate Cancer Screening – 2022 Program: Testing and Early Diagnosis

Prostate Cancer Treatment 1 Min Read

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University…

The Importance of Patient Centered Care – 2022 Program: Testing and Early Diagnosis

General 1 Min Read

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University…

Efficiency and Effectiveness of Cancer Care – 2022 Program: Testing and Early Diagnosis

Lung Cancer Treatment 1 Min Read

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University…

Efficiency and Effectiveness of Cancer Care – 2022 Program: Testing and Early Diagnosis

General 1 Min Read

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University…

Timeliness in Cancer Care – 2022 Program: Testing and Early Diagnosis

Lung Cancer Treatment 1 Min Read

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University…

Goals of Lung Cancer Advocacy – Goals of Lung Cancer Advocacy

Lung Cancer Treatment 1 Min Read

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University…

Key Players for Lung Cancer Program Success – 2022 Program: Testing and Early Diagnosis

Lung Cancer Treatment 1 Min Read

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University…

What is Involved in Lung Cancer Screening? – 2022 Program: Testing and Early Diagnosis

Lung Cancer Treatment 1 Min Read

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University…

Who Should Receive Lung Cancer Screening? – 2022 Program: Testing and Early Diagnosis

Lung Cancer Treatment 1 Min Read

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University…

Covid and Lung Cancer Screening – 2022 Program: Testing and Early Diagnosis

Lung Cancer Treatment 1 Min Read

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University…

Biomarker Testing for NSCLC:The Importance and the Disparities-2022 Program:Targeted Therapies Forum

Non-Small Cell Lung Cancer 1 Min Read

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe…

Liquid Biopsies in NSCLC – 2022 Program: Targeted Therapies Forum – English

Non-Small Cell Lung Cancer 1 Min Read

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe…

Advanced ALK+, RET+ and MET+ NSCLC – 2022 Program: Targeted Therapies Forum – English

Non-Small Cell Lung Cancer 1 Min Read

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe…

Resources and Tools: Part 7 – High Quality Decisions in Prostate Cancer with Dr. Kwon

Prostate Cancer Treatment 1 Min Read

For this series, Dr. Kwon discusses the decision-making process with Fred, who has recurrent prostate cancer and is making an…

Personal Preferences: Part 6 – High-Quality Decisions in Prostate Cancer with Dr. Kwon

Prostate Cancer Treatment 1 Min Read

For this series, Dr. Kwon discusses the decision-making process with Fred, who has recurrent prostate cancer and is making an…

Starting Hormone Treatment Later: Part 4 – High Quality Decisions in Prostate Cancer with Dr. Kwon

Prostate Cancer Treatment 1 Min Read

For this series, Dr. Kwon discusses the decision-making process with Fred, who has recurrent prostate cancer and is making an…

KRAS Mutations in Advanced NSCLC – 2022 Program: Targeted Therapies Forum – English

Non-Small Cell Lung Cancer 1 Min Read

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe…

Exon 20 and HER2: The Destiny Trial – 2022 Program: Targeted Therapies Forum – English

Non-Small Cell Lung Cancer 1 Min Read

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe…

ADAURA Trial: Osimertinib for Early Stage EGFR+ NSCLC – 2022 Program: Targeted Therapies Forum

Non-Small Cell Lung Cancer 1 Min Read

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe…

Amivantamab and Lazertinib in EGFR MET+ Disease – 2022 Program: Targeted Therapies Forum – English

Non-Small Cell Lung Cancer 1 Min Read

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe…

Acquired Resistance to Osimertinib in EGFR+ NSCLC – 2022 Program: Targeted Therapies Forum – English

Non-Small Cell Lung Cancer 1 Min Read

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe…

Starting Hormone Treatment Immediately: Part 5, High-Quality Decisions – Prostate Cancer, Dr. Kwon

Prostate Cancer Treatment 1 Min Read

For this series, Dr. Kwon discusses the decision-making process with Fred, who has recurrent prostate cancer and is making an…

Treatment Options: Part 3 – High Quality Decisions in Prostate Cancer with Dr. Kwon

Prostate Cancer Treatment 1 Min Read

For this series, Dr. Kwon discusses the decision-making process with Fred, who has recurrent prostate cancer and is making an…

Treatment of EGFR Mutated NSCLC – 2022 Program: Targeted Therapies Forum – English

Non-Small Cell Lung Cancer 1 Min Read

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe…

Advantages of Next Generation Sequencing in NSCLC – 2022 Program: Targeted Therapies Forum – English

Non-Small Cell Lung Cancer 1 Min Read

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe…

Prevalence of Targeted Driver Mutations in NSCLC – 2022 Program: Targeted Therapies Forum – English

Non-Small Cell Lung Cancer 1 Min Read

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe…

Changes in the Field of Metastatic NSCLC – 2022 Program: Targeted Therapies Forum – English

Non-Small Cell Lung Cancer 1 Min Read

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe…

Emerging Treatments for Oral Mucositis – ASCO Recaps Head and Neck Cancer Patient Education

Head and Neck 1 Min Read

In this video series Dr. Kathryn Gold, Medical Oncologist, specialized in lung, head and neck, Professor, Department of Medicine, UC…

Circulating Tumor (CT) and HPV DNA – ASCO Recaps Head and Neck Cancer Patient Education

Head and Neck 1 Min Read

In this video series Dr. Kathryn Gold, Medical Oncologist, specialized in lung, head and neck, Professor, Department of Medicine, UC…

Combination Therapy for Head and Neck Cancer – ASCO Recaps Head and Neck Cancer Patient Education

Head and Neck 1 Min Read

In this video series Dr. Kathryn Gold, Medical Oncologist, specialized in lung, head and neck, Professor, Department of Medicine, UC…

Recurrent or Metastatic Head and Neck Cancer – ASCO Recaps Head and Neck Cancer Patient Education

Head and Neck 1 Min Read

In this video series Dr. Kathryn Gold, Medical Oncologist, specialized in lung, head and neck, Professor, Department of Medicine, UC…

Immunotherapy Treatments in Patients with Head and Neck Cancer – ASCO Recaps Head and Neck Cancer

Head and Neck 1 Min Read

In this video series Dr. Kathryn Gold, Medical Oncologist, specialized in lung, head and neck, Professor, Department of Medicine, UC…

Nonsurgical Treatment in Head and Neck Cancer: Weekly Cisplatin – ASCO Recaps Head and Neck Cancer

Head and Neck 1 Min Read

In this video series Dr. Kathryn Gold, Medical Oncologist, specialized in lung, head and neck, Professor, Department of Medicine, UC…

Deintensification for Nasopharyngeal Cancer – ASCO Recaps Head and Neck Cancer Patient Education

Head and Neck 1 Min Read

In this video series Dr. Kathryn Gold, Medical Oncologist specializing in lung, head and neck cancers, Professor with the Department…

Guía del paciente – Visita inicial de oncología médica – Programa PEA 2021-22

General 1 Min Read

El Dr. Eric Singh, uno de los participantes en el Programa de Embajadores de Educación para Pacientes GRACE del año…

A Patient’s Guide to the Initial Medical Oncology Visit – Patient Ed. Ambassadors Program 2021-22

General 1 Min Read

Dr. Eric Singh, one of the participants in this past year’s GRACE Patient Education Ambassador Program, produced this great video…

Checkmate 816: Combining Chemo and Opdivo – ASCO Lung Review 2022

Non-Small Cell Lung Cancer 1 Min Read

For this year’s post-ASCO Lung Cancer roundtable review, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center and…

The Skyscraper Trial: Treatments for Extensive Stage Small Cell Lung Cancer – ASCO Lung Review 2022

Small Cell Lung Cancer 1 Min Read

For this year’s post-ASCO Lung Cancer roundtable review, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center and…

Patritumab Deruxtecan: Use in Previously Treated Patients Without Mutations – ASCO Lung Review 2022

Non-Small Cell Lung Cancer 1 Min Read

For this year’s post-ASCO Lung Cancer roundtable review, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center and…

EGFRm+ NSCLC: Should We Treat with Durvalumab? – ASCO Lung Review 2022

Non-Small Cell Lung Cancer 1 Min Read

For this year’s post-ASCO Lung Cancer roundtable review, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center and…

Rybrevant/Lazertinib for EGFRm+ Acquired Resistance – ASCO Lung Review 2022

Non-Small Cell Lung Cancer 1 Min Read

For this year’s post-ASCO Lung Cancer roundtable review, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center and…

Keytruda Combined with Anti-VEGF Treatment:Use in Patients with Advanced NSCLC-ASCO Lung Review 2022

Non-Small Cell Lung Cancer 1 Min Read

For this year’s post-ASCO Lung Cancer roundtable review, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center and…

Adagrasib for Previously Treated KRAS G12C+ NSCLC – ASCO Lung Review 2022

Non-Small Cell Lung Cancer 1 Min Read

For this year’s post-ASCO Lung Cancer roundtable review, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center and…

Chemotherapy and Immunotherapy for Patients with KRAS Mutations – ASCO Lung Review 2022

Non-Small Cell Lung Cancer 1 Min Read

For this year’s post-ASCO Lung Cancer roundtable review, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center and…

Patients with High PD-L1: Immunotherapy Alone or Combine with Chemo? – ASCO Lung Review 2022

Non-Small Cell Lung Cancer 1 Min Read

For this year’s post-ASCO Lung Cancer roundtable review, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center and…

The Need for Molecular Testing in Lung Cancer – ASCO Lung Review 2022

Non-Small Cell Lung Cancer 1 Min Read

For this year’s post-ASCO Lung Cancer roundtable review, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center and…

Diagnosis and Staging of Mesothelioma 间皮瘤的诊断和分期 East Asian Lung Cancer Video Library

Lung Cancer Treatment 1 Min Read

For our Mandarin-speaking community, GRACE is happy to offer updates to our Lung Cancer Video Library translated and voiced by…

Future Approaches to Treating Mesothelioma 治疗间皮瘤的未来方法 – East Asian Lung Cancer Library

Lung Cancer Treatment 1 Min Read

For our Mandarin-speaking community, GRACE is happy to offer updates to our Lung Cancer Video Library translated and voiced by…

Amivantamab 和 Mobocertinib:用于对抗 EGFR 外显子 20 插入突变 East Asian Lung Cancer Video Library

Non-Small Cell Lung Cancer 1 Min Read

For our Mandarin-speaking community, GRACE is happy to offer updates to our Lung Cancer Video Library translated and voiced by…

MET Exon-14 在非小细胞肺癌中的跳跃 – East Asian Lung Cancer Video Library

Non-Small Cell Lung Cancer 1 Min Read

For our Mandarin-speaking community, GRACE is happy to offer updates to our Lung Cancer Video Library translated and voiced by…

EGFR-Exon 20 的新兴治疗和临床试验 East Asian Lung Cancer Video Library

Non-Small Cell Lung Cancer 1 Min Read

For our Mandarin-speaking community, Oliver Zheng offers translated updates to our Lung Cancer Video Library. In this video translation, Dr.…

Prevención del cáncer de cabeza y cuello: vacunas y más – Pruebas y diagnóstico temprano

Head and Neck 1 Min Read

El Dr. Jared Weiss se une a nosotros para analizar la importancia de las pruebas y el diagnóstico temprano en…

La importancia y los beneficios de las pruebas de detección: pruebas y diagnóstico temprano

Head and Neck 1 Min Read

El Dr. Jared Weiss se une a nosotros para analizar la importancia de las pruebas y el diagnóstico temprano en…

Factores de riesgo para los cánceres de cabeza y cuello – Español – Pruebas y diagnóstico temprano

Head and Neck 1 Min Read

El Dr. Jared Weiss se une a nosotros para analizar la importancia de las pruebas y el diagnóstico temprano en…

Head and Neck Cancer Prevention: Vaccines and More – Testing and Early Diagnosis

Head and Neck 1 Min Read

Dr. Jared Weiss joins us to discuss the importance of testing and early diagnosis in cancer care, with a concentration…

The Importance and Benefits of Screening – Testing and Early Diagnosis

Head and Neck 1 Min Read

Dr. Jared Weiss joins us to discuss the importance of testing and early diagnosis in cancer care, with a concentration…

Risk Factors for Head and Neck Cancers – Testing And Early Diagnosis

Head and Neck 1 Min Read

Dr. Jared Weiss joins us to discuss the importance of testing and early diagnosis in cancer care, with a concentration…

Full Video OnDemand – 2022 Spanish Targeted Therapies Patient Forum

Non-Small Cell Lung Cancer 1 Min Read

July 30, 2022 – full ONDEMAND video For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Stage 3 Squamous Lung Cancer with Low PD-L1 – Case Based Panel Discussion

Non-Small Cell Lung Cancer 1 Min Read

For this year’s update to the Case-Based Panel Discussions program, we are pleased to work with Drs. Ana Velazquez Mañana,…

Non-Bulky NSCLC 2B Disease: The Role of Chemoimmunotherapy – Case Based Panel Discussion

Non-Small Cell Lung Cancer 1 Min Read

For this year’s update to the Case-Based Panel Discussions program, we are pleased to work with Drs. Ana Velazquez Mañana,…

Stage 3A Node-Positive Lung Adenocarcinoma with ALK Rearrangement – Case Based Panel Discussions

Non-Small Cell Lung Cancer 1 Min Read

For this year’s update to the Case-Based Panel Discussions program, we are pleased to work with Drs. Ana Velazquez Mañana,…

Stage 2 Lung Adenocarcinoma: Biomarkers & Treatment Approaches – Case-Based Panel Discussions

Non-Small Cell Lung Cancer 1 Min Read

For this year’s update to the Case-Based Panel Discussions program, we are pleased to work with Drs. Ana Velazquez Mañana,…

Testing Methods to Discover RET+ Disease – Lung Cancer Video Library

Non-Small Cell Lung Cancer 2 Mins Read

We are excited to bring new and updated information to share through our Lung Cancer Video Library. For this video…

RET+ Mutation in NSCLC – Lung Cancer Video Library

Non-Small Cell Lung Cancer 2 Mins Read

We are excited to bring new and updated information to share through our Lung Cancer Video Library. For this video…

Immunotherapy for Patients with Driver Mutation – Lung Cancer Video Library

Non-Small Cell Lung Cancer 2 Mins Read

We are excited to bring new and updated information to share through our Lung Cancer Video Library. For this video…

Sociodemographic: SABCS 2022 Megan Kruse Disparities in AYA Breast Cancer

Breast Cancer 9 Mins Read

Sociodemographic: SABCS 2022 Megan Kruse Disparities in AYA Breast Cancer What does the sociodemographics present study of Adolescent and Young…

Sociodemographic: SABCS 2022 Megan Kruse Disparities in AYA Breast Cancer

Breast Cancer 9 Mins Read

Sociodemographic: SABCS 2022 Megan Kruse Disparities in AYA Breast Cancer What does the sociodemographics present study of Adolescent and Young…

Sociodemographic: SABCS 2022 Megan Kruse Disparities in AYA Breast Cancer

Breast Cancer 9 Mins Read

iFrame is not supported! Sociodemographic: SABCS 2022 Megan Kruse Disparities in AYA Breast Cancer What does the sociodemographics present…

DESTINY-Breast03: SABCS 2022 Sara Hurvitz Updated Survival Results

Breast Cancer 9 Mins Read

DESTINY-Breast03: SABCS 2022 Sara Hurvitz Updated Survival Results What do the updated survival results deruxtecan versus trastuzumab emtansine reveal for…

DESTINY-Breast03: SABCS 2022 Sara Hurvitz Updated Survival Results

Breast Cancer 9 Mins Read

iFrame is not supported! DESTINY-Breast03: SABCS 2022 Sara Hurvitz Updated Survival Results What do the updated survival results deruxtecan…

DESTINY-Breast03: SABCS 2022 Sara Hurvitz Updated Survival Results

Breast Cancer 9 Mins Read

DESTINY-Breast03: SABCS 2022 Sara Hurvitz Updated Survival Results What do the updated survival results deruxtecan versus trastuzumab emtansine reveal for…

GC012F: ASH 2022 Wendy Li First-Line Therapy Newly Diagnosed MM

Multiple Myeloma 5 Mins Read

GC012F: ASH 2022 Wendy Li First-Line Therapy Newly Diagnosed MM By Wendy Li, MD How can GC012F help patients with…

GC012F: ASH 2022 Wendy Li First-Line Therapy Newly Diagnosed MM

Multiple Myeloma 5 Mins Read

iFrame is not supported! GC012F: ASH 2022 Wendy Li First-Line Therapy Newly Diagnosed MM By Wendy Li, MD How can…

GC012F: ASH 2022 Wendy Li First-Line Therapy Newly Diagnosed MM

Multiple Myeloma 5 Mins Read

GC012F: ASH 2022 Wendy Li First-Line Therapy Newly Diagnosed MM By Wendy Li, MD How can GC012F help patients with…

IHC 0 HER2: SABCS 2022 Gerard Oakley Deep Learning-Based Assessment

Breast Cancer 24 Mins Read

IHC 0 HER2: SABCS 2022 Gerard Oakley Deep Learning-Based Assessment By Gerard Oakley, MD What is IHC 0 in HER2…

IHC 0 HER2: SABCS 2022 Gerard Oakley Deep Learning-Based Assessment

Breast Cancer 24 Mins Read

iFrame is not supported! IHC 0 HER2: SABCS 2022 Gerard Oakley Deep Learning-Based Assessment By Gerard Oakley, MD What is…

IHC 0 HER2: SABCS 2022 Gerard Oakley Deep Learning-Based Assessment

Breast Cancer 24 Mins Read

IHC 0 HER2: SABCS 2022 Gerard Oakley Deep Learning-Based Assessment By Gerard Oakley, MD What is IHC 0 in HER2…

CLL Treatments: ASH 2022 Brian Koffman Understanding Pts with CLL

Chronic Lymphocytic Leukemia 10 Mins Read

CLL Treatments: ASH 2022 Brian Koffman Understanding Pts with CLL By Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd How…

CLL Treatments: ASH 2022 Brian Koffman Understanding Pts with CLL

Acute Lymphoblastic Leukemia 10 Mins Read

iFrame is not supported! CLL Treatments: ASH 2022 Brian Koffman Understanding Pts with CLL By Brian Koffman, MDCM (retired), DCFP,…

CLL Treatments: ASH 2022 Brian Koffman Understanding Pts with CLL

Chronic Lymphocytic Leukemia 10 Mins Read

CLL Treatments: ASH 2022 Brian Koffman Understanding Pts with CLL By Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd How…

Navitoclax: ASH 2022 Jalaja Potluri Disease Modification in Myelofibrosis

Myeloproliferative Disease 9 Mins Read

Navitoclax: ASH 2022 Jalaja Potluri Disease Modification in Myelofibrosis By Jalaja Potluri, MD How can this study help modify myelofibrosis?…

Navitoclax: ASH 2022 Jalaja Potluri Disease Modification in Myelofibrosis

Myeloproliferative Disease 9 Mins Read

iFrame is not supported! Navitoclax: ASH 2022 Jalaja Potluri Disease Modification in Myelofibrosis By Jalaja Potluri, MD How can this…

Navitoclax: ASH 2022 Jalaja Potluri Disease Modification in Myelofibrosis

Myeloproliferative Disease 9 Mins Read

Navitoclax: ASH 2022 Jalaja Potluri Disease Modification in Myelofibrosis By Jalaja Potluri, MD How can this study help modify myelofibrosis?…

TriTAC: ASH 2022 Al-Ola Abdallah Updated Interim Results HBN217

Acute Lymphoblastic Leukemia 7 Mins Read

TriTAC: ASH 2022 Al-Ola Abdallah Updated Interim Results HBN217 By Al-Ola Abdallah, MD What are the updated interim results from…

TriTAC: ASH 2022 Al-Ola Abdallah Updated Interim Results HBN217

Acute Lymphoblastic Leukemia 7 Mins Read

iFrame is not supported! TriTAC: ASH 2022 Al-Ola Abdallah Updated Interim Results HBN217 By Al-Ola Abdallah, MD What are the…

TriTAC: ASH 2022 Al-Ola Abdallah Updated Interim Results HBN217

Multiple Myeloma 7 Mins Read

TriTAC: ASH 2022 Al-Ola Abdallah Updated Interim Results HBN217 By Al-Ola Abdallah, MD What are the updated interim results from…

Asciminib: ASH 2022 Prof. Tim Hughes Studies For patients With CML

Chronic Myelogenous Leukemia 7 Mins Read

Asciminib: ASH 2022 Prof. Hughes Studies For Pts With CML By Professor Timothy Hughes, MD, MBBS, FRACP, FRCPA How can…

Asciminib: ASH 2022 Prof. Hughes Studies For Pts With CML

Chronic Myelogenous Leukemia 7 Mins Read

iFrame is not supported! Asciminib: ASH 2022 Prof. Hughes Studies For Pts With CML By Professor Timothy Hughes, MD, MBBS,…

Asciminib: ASH 2022 Prof. Hughes Studies For Pts With CML

Chronic Myelogenous Leukemia 7 Mins Read

Asciminib: ASH 2022 Prof. Hughes Studies For Pts With CML By Professor Timothy Hughes, MD, MBBS, FRACP, FRCPA How can…

Liso-cel: ASH 2022 Yuliya Linhares Data From the Outreach Study

Lymphoma 12 Mins Read

Liso-cel: ASH 2022 Data From the Outreach Study By Yuliya Linhares, MD How can Liso-Cell (Lisocabtagene Maraleucel) help patients with…

Liso-cel: ASH 2022 Yuliya Linhares Data From the Outreach Study

Lymphoma 12 Mins Read

iFrame is not supported! Liso-cel: ASH 2022 Data From the Outreach Study By Yuliya Linhares, MD How can Liso-Cell (Lisocabtagene…

Liso-cel: ASH 2022 Yuliya Linhares Data From the Outreach Study

Lymphoma 12 Mins Read

Liso-cel: ASH 2022 Data From the Outreach Study By Yuliya Linhares, MD How can Liso-Cell (Lisocabtagene Maraleucel) help patients with…

RxPONDER: SABCS 2022 Yara Abdou Racial Disparities SWOG S1007

Breast Cancer 6 Mins Read

RxPONDER: SABCS 2022 Yara Abdou Racial Disparities SWOG S1007 The focus was on patient-reported anxiety and fatigue in women,…

RxPONDER: SABCS 2022 Yara Abdou Racial Disparities SWOG S1007

Breast Cancer 6 Mins Read

iFrame is not supported! RxPONDER: SABCS 2022 Yara Abdou Racial Disparities SWOG S1007 The focus was on patient-reported anxiety…

RxPONDER: SABCS 2022 Yara Abdou Racial Disparities SWOG S1007

Breast Cancer 6 Mins Read

RxPONDER: SABCS 2022 Yara Abdou Racial Disparities SWOG S1007 The focus was on patient-reported anxiety and fatigue in women,…

Previous 1 2 3 4 5 6 … 50 Next
Recent Posts
  • ESMO 2025 Top 10 Breast Cancer Abstracts: 10 Positive Breakthroughs
  • TCR-T Therapy: 49% Risk Cut & 39% Response
  • ESMO 2025 Top 10 Genitourinary Cancer Must-See Abstracts: 78% rPFS Boost Unveiled
  • Immune Checkpoint Inhibitors Myocarditis: 1% Risk, 50% Fatal – UCSF Insights
  • TIL Therapy Breakthroughs for Oncologists and Oncology Professionals
Connect With Us on Social
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
X (Twitter) LinkedIn Facebook YouTube
  • FDA
  • Conferences
    • AACR
    • ASBRS
    • ASCO
    • SABCS
    • ASH
    • ESMO
    • MOASC
    • Upcoming Oncology Conferences
  • Cancers
    • Breast Cancer
    • Prostate Cancer Treatment
    • Lung Cancer Treatment
    • Gastrointestinal Cancer Treatment
    • Melanoma Skin Cancer Treatment
    • Non-Hodgkin Lymphoma
    • Kidney
    • Acute Lymphoblastic Leukemia
    • Acute Myelogenous Leukemia
    • Bone Metastases
    • Brain
    • Business Management
    • Cervical
    • Chronic Lymphocytic Leukemia
    • Chronic Myelogenous Leukemia
    • Colorectal
    • COVID-19
    • General
    • Genitourinary
    • Head and Neck
    • Help
    • Hematologic Malignancies
    • Hodgkin Lymphoma
    • Imaging
    • Immunotherapy
    • Liver
    • Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Disease
    • News
    • Non-Small Cell Lung Cancer
    • Other
    • Ovarian
    • Pancreatic
    • Patient Resources
    • Pediatric
    • Sarcoma
    • Sickle Cell
    • Small Cell Lung Cancer
    • Supportive Care
    • Testicular
    • Urology
    • Uterine
  • About
  • Contact
  • Advertise
    • Advertising and Services – Media Kit 2025 – OncologyTube.com
    • Oncology Press Release Distribution
© 2025 Copyright Protected Medicus Networks, Inc. Privacy Policy

Type above and press Enter to search. Press Esc to cancel.